文献速递胃肠外科围术期管理与 ERAS

早期食管癌系统性淋巴结清扫与选择性淋巴结清扫的近期与远期疗效比较

[A comparative study of the short-term efficacy and long-term efficacy of systematic lymph node dissection and elective lymph node dissection in patients with early esophageal cancer].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2018-01-01

该回顾性研究纳入405例cT1N0M0期食管癌患者,比较系统性淋巴结清扫(SLND,208例)与选择性淋巴结清扫(ELND,197例)的安全性及疗效。结果显示SLND组术后并发症发生率更高,但两组总体1、3、5年生存率无显著差异;分层分析中Ⅱa期患者SLND组生存率优于ELND组(P=0.047)。结论认为ELND可安全有效地用于早期食管癌。

要点

  • SLND组术后肺部感染、心律失常、乳糜胸及需再次手术出血的发生率均高于ELND组。
  • 两组总体1、3、5年生存率无显著差异,Ⅰ期患者亚组亦无差异。
  • Ⅱa期患者SLND组1、3、5年生存率(100%、94.5%、83.2%)优于ELND组(100%、91.3%、72.1%),P=0.047。

核心结论

  • ELND可较安全有效地治疗Ⅰ期食管癌,远近期疗效良好。

研究设计与样本

  • 回顾性收集2007年3月至2013年3月在中国科技大学附属第一医院胸外科接受微创食管癌切除术的405例cT1N0M0期食管癌患者资料。
  • 按淋巴结清扫方式分为SLND组208例和ELND组197例,比较临床病理、围手术期资料及生存率。

主要发现

  • SLND组术后微小并发症中肺部感染(8.2%比2.9%,P=0.04)和心律失常(6.2%比2.0%,P=0.03)发生率高于ELND组。
  • SLND组术后重大并发症中肺部感染(6.2%比2.0%,P=0.03)、乳糜胸(5.8%比1.5%,P=0.02)、需再次手术的吻合口或胸腔出血(2.9%比0.5%,P=0.04)发生率高于ELND组。
  • SLND组与ELND组1、3、5年生存率无明显差异;Ⅰ期患者两组生存率亦无明显差异。
  • Ⅱa期患者SLND组1、3、5年生存率(100%、94.5%、83.2%)优于ELND组(100%、91.3%、72.1%),P=0.047。
  • SLND组平均清扫淋巴结数目30.2±4.2枚、站数12.1±2.7站;ELND组分别为25.7±3.8枚、8.4±3.6站。

临床怎么用

  • 对于早期食管癌,ELND可作为一种安全有效的淋巴结清扫策略,术后并发症较少。
  • Ⅱa期患者可能从SLND中获得生存获益,需个体化选择清扫范围。

局限性

  • 本研究为单中心回顾性研究,可能存在选择偏倚。
  • 样本来自2007年至2013年,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the feasibility, safety, short-term efficacy and long-term efficacy of elective lymph node dissection in patients with early esophageal cancer. Methods: The study retrospectively evaluated 405 patients with cT1N0M0 esophageal carcinoma who received minimally invasive esophagectomy in the First Affiliated Hospital of University of Science and Technology of China between March 2007 and March 2013. Of those patients, 208 patients underwent systematic lymph node dissection (SLND) and 197 patients underwent elective lymph node dissection (ELND). The clinicopathologic factors, operational factors, postoperative complications, lymph node dissection and prognosis of patients were compared by independent sample t test, χ(2) test, or Mann-Whitney rank test. The 5-year overall survival was calculated by the Kaplan-Meier estimation method using the Log-rank test. Results: There was no significant difference in clinicopathological data between the SLND group and the ELND group. The incidence of pulmonary infection (8.2% vs. 2.9%, P=0.04) and arrhythmia (6.2% vs. 2.0%, P=0.03) of the minor postoperative complications in the SLND group were higher than the ELND group. The incidence of pulmonary infection (6.2% vs. 2.0%, P=0.03), Chylothorax (5.8% vs.1.5%, P=0.02), anastomotic or pleural hemorrhage requiring reoperation (2.9% vs.0.5%, P=0.04) of major postoperative complications in the SLND group were higher than the ELND group, the difference was statistically significant. In the perioperative data of two groups, the incidence of total postoperative complications, total pulmonary complications, operation time, intraoperative blood loss, postoperative hospitalization, postoperative thoracic drainage duration and postoperative thoracic drainage fluid volume of the SLND group were higher than the ELND group, the difference was statistically significant. The mean numbers and stations of dissected lymph node in the SLND were 30.2±4.2 and 12.1±2.7, the mean numbers and stations of dissected lymph node in the ELND were 25.7±3.8 and 8.4±3.6. The survival rates of 1, 3, 5 years of all patients were 100%, 95.9% and 82.5%, respectively. The median survival time was 87.4 months. Further analysis showed that the 1, 3 and 5 years survival rate of patients with stage Ⅰ esophageal cancer was 100%, 97.1% and 88.9%, respectively. The median survival time was 89.3 months. The 1, 3 and 5 years survival rate of patients with stage Ⅱa esophageal cancer was 100%, 93.2% and 76.8%, respectively. The median survival time was 77.2 months. There was no significant difference in survival rate between the SLND group and the ELND group in 1, 3 and 5 years. When taking a further analysis of stage Ⅰ esophageal cancer, the survival rates between 188 patients in the SLND group and 180 patients in the ELND group were no significant difference. When focus on the stage Ⅱa esophageal cancer, the 1, 3 and 5 years survival rate were higher in the SLND group than that in the ELND group (100%, 94.5%, 83.2% vs. 100%, 91.3%, 72.1%, P=0.047), the difference was statistically significant. Conclusion: ELND can be safely and effectively performed for early esophageal cancer with favorable short-term efficacy and long-term efficacy. 目的: 探讨选择性淋巴结清扫术(ELND)治疗早期食管癌的安全性、有效性和远近期疗效。 方法: 回顾性收集2007年3月至2013年3月期间在中国科技大学附属第一医院胸外科接受微创食管癌切除术的405例cT1N0M0期食管癌患者的临床资料,根据术中淋巴结清扫方式不同分为系统性淋巴结清扫(SLND)组208例和ELND组197例。采用t检验、χ(2)检验或Wilcoxon秩和检验比较两组患者的临床病理学资料、围手术期资料、淋巴结清扫情况,采用Kaplan-Meier法计算生存率并绘制生存曲线,Log-rank检验比较生存率。 结果: 两组患者的临床病理学资料无明显差异。在术后微小并发症中,SLND组的肺部感染(8.2%比2.9%,P=0.04)和心律失常(6.2%比2.0%,P=0.03)发生率高于ELND组,在术后重大并发症中,SLND组的肺部感染(6.2%比2.0%,P=0.03)、乳糜胸(5.8%比1.5%,P=0.02)、需再次手术的吻合口或胸腔出血的发生率(2.9%比0.5%,P=0.04)高于ELND组。SLND组和ELND组的1、3、5年生存率无明显差异。分层分析结果显示,Ⅰ期食管癌患者两组的1、3、5年生存率无明显差异,Ⅱa期患者SLND组的1、3、5年生存率优于ELND组(100%、94.5%、83.2%比100%、91.3%、72.1%,P=0.047)。 结论: ELND可较安全有效地治疗Ⅰ期食管癌,远近期疗效良好。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wu HR, Liu CQ, Guo MF, et al. [A comparative study of the short-term efficacy and long-term efficacy of systematic lymph node dissection and elective lymph node dissection in patients with early esophageal cancer]. Zhonghua Wai Ke Za Zhi. 2018. PMID: 30157578. doi:10.3760/cma.j.issn.0529-5815.2018.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。